相关实验视频

Updated: Jul 24, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

循环miRNAs驱动个性化药物基于亚组分类在肌痛性骨髓灰质炎患者

Xiaoyu Huang^1,2, Zhouao Zhang¹, Yingying Wang¹

¹Department of Neurology, Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Quanshan Distric, Xuzhou, Jiangsu, China.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|July 4, 2023

概括

本综述探讨了循环中的microRNAs (miRNAs) 作为肌痛性骨髓灰质炎 (MG) 亚组的潜在生物标志物. 了解这些miRNA差异可以推进这种自身免疫神经肌肉疾病的个性化治疗策略.

科学领域:

神经学神经学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

骨髓灰质炎 (MG) 是一种异质的自身免疫神经肌肉疾病,需要精确的治疗策略.
目前的MG分类包括基于抗体和临床表现的子组,但缺乏治疗反应的客观生物标志物.
微RNAs (miRNAs) 是基因表达的关键调节者,并与自身免疫性疾病的病原发生有关,包括MG.

研究的目的:

系统地审查和总结循环微RNAs (miRNAs) 在不同肌痛性骨髓灰质炎 (MG) 亚组中的作用.
突出循环miRNAs作为客观生物标志物的潜力,用于预测和监测MG患者个性化治疗反应.

主要方法:

对研究的系统文献综述,这些研究调查了各种肌痛性骨髓灰质炎 (MG) 亚组中的循环miRNAs.
分析报告的miRNA表达特征及其与MG患者临床特征和抗体状况的相关性.

主要成果:

循环的miRNA配置文件显示了不同MG子组的不同模式,包括眼部MG,抗体相关的MG (AchR,MuSK,LRP4),胸腺瘤相关的MG和血清阴性MG.
这些miRNA差异表明它们作为MG亚型和治疗指导的特定生物标志物的潜力.

结论:

循环中的miRNAs代表了有希望的,客观的生物标志物,用于将肌痛性硬化症 (MG) 患者分为不同的亚组.
对循环miRNA的进一步研究可以促进开发个性化医疗方法来管理MG.

关键词:

微RNAs是一种微RNA.骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.个性化医疗是个性化的医疗.小组分类分类子组分类

更多相关视频

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...